局部激素联合家庭窄谱UVB治疗局限性白癜风的成本效果分析
本研究基于一项实用型三臂安慰剂对照随机试验,纳入517例活动期且皮损面积<10%的成人和儿童白癜风患者,比较局部激素(TCS)、家庭窄谱UVB(NB-UVB)及两者联合的成本效果。结果显示,联合治疗相比单用TCS每增加一例成功治疗的成本为1932英镑,低于单用NB-UVB的3336英镑。
要点
- 联合治疗每增加一例成功治疗的成本为1932英镑。
- 单用NB-UVB每增加一例成功治疗的成本为3336英镑。
- 若决策者愿意支付1932英镑/额外成功治疗,联合治疗具成本效果。
核心结论
- 联合治疗相比单用TCS每增加一例成功治疗的增量成本低于单用NB-UVB。
- 若决策者愿意支付1932英镑/额外成功治疗,联合治疗可被认为具有成本效果。
研究设计与样本
- 基于实用型、三臂、安慰剂对照随机对照试验的成本效果分析,治疗9个月。
- 共纳入517例年龄≥5岁、活动期白癜风且皮损面积<10%的成人和儿童,按1:1:1随机分配至TCS、NB-UVB或联合治疗组。
主要发现
- 联合治疗每增加一例成功治疗的增量成本为1932英镑。
- NB-UVB每增加一例成功治疗的增量成本为3336英镑。
关键数值与推荐
- 成本效果以每例成功治疗(采用Vitiligo Noticeability Scale评估)的成本表示。
- 次要成本效用分析使用EuroQol 5 Dimensions 5 Levels(≥11岁)和Child Health Utility 9D(5至<18岁)测量质量调整生命年。
临床怎么用
- 对于活动期且皮损面积<10%的局限性白癜风,联合治疗相比单用TCS每增加一例成功治疗的增量成本低于单用NB-UVB。
- 决策者若愿意支付1932英镑/额外成功治疗,联合治疗可视为具有成本效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Economic evidence for vitiligo treatments is absent. OBJECTIVES: To determine the cost-effectiveness of (i) handheld narrowband ultraviolet B (NB-UVB) and (ii) a combination of topical corticosteroid (TCS) and NB-UVB compared with TCS alone for localized vitiligo. METHODS: Cost-effectiveness analysis alongside a pragmatic, three-arm, placebo-controlled randomized controlled trial with 9 months' treatment. In total 517 adults and children (aged ≥ 5 years) with active vitiligo affecting < 10% of skin were recruited from secondary care and the community and were randomized 1: 1: 1 to receive TCS, NB-UVB or both. Cost per successful treatment (measured on the Vitiligo Noticeability Scale) was estimated. Secondary cost-utility analyses measured quality-adjusted life-years using the EuroQol 5 Dimensions 5 Levels for those aged ≥ 11 years and the Child Health Utility 9D for those aged 5 to < 18 years. The trial was registered with number ISRCTN17160087 on 8 January 2015. RESULTS: The mean ± SD cost per participant was £775 ± 83·7 for NB-UVB, £813 ± 111.4 for combination treatment and £600 ± 96·2 for TCS. In analyses adjusted for age and target patch location, the incremental difference in cost for combination treatment compared with TCS was £211 (95% confidence interval 188-235), corresponding to a risk difference of 10·9% (number needed to treat = 9). The incremental cost was £1932 per successful treatment. The incremental difference in cost for NB-UVB compared with TCS was £173 (95% confidence interval 151-196), with a risk difference of 5·2% (number needed to treat = 19). The incremental cost was £3336 per successful treatment. CONCLUSIONS: Combination treatment, compared with TCS alone, has a lower incremental cost per additional successful treatment than NB-UVB only. Combination treatment would be considered cost-effective if decision makers are willing to pay £1932 per additional treatment success.
引用
- Sach TH, Thomas KS, Batchelor JM, et al. An economic evaluation of the randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo (the HI-Light Vitiligo Trial). Br J Dermatol. 2020. PMID: 32920824. doi:10.1111/bjd.19554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。